Mustang Bio (MBIO) risk factors
Item 1A of every Mustang Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors64 risks7 new7 dropped12 reworded
Mustang Bio faces heightened regulatory, pricing, and funding scrutiny under government policies like the ACA, IRA, and Medicaid rebate changes. The company completed a public offering and reverse stock split to regain compliance with Nasdaq listing rules. Cybersecurity, third-party reliance, and climate-related operational disruptions remain critical risk themes.
Filed Mar 19, 2026 - FY2024 10-K risk factors64 risks
Company is an early-stage biotechnology firm relying entirely on third parties for clinical trials, manufacturing, and research. Heavy capital needs, reliance on CAR T technology, and extensive healthcare regulation dominate the risk profile.
Filed Mar 28, 2025